Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)

Journal of Medicinal Chemistry

Volumn 59, Issue 1, 2016, Pages 206-218

  Yang, Xing ^a   Mease, Ronnie C ^a   Pullambhatla, Mrudula ^a   Lisok, Ala ^a   Chen, Ying ^a   Foss, Catherine A ^a   Wang, Yuchuan ^a   Shallal, Hassan ^a   Edelman, Hannah ^a   Hoye, Adam T ^b   Attardo, Giorgio ^b   Nimmagadda, Sridhar ^a   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (TERT BUTOXY) 6 [(TERT BUTOXYCARBONYL)AMINO] 1 OXOHEXAN 2 YL 1H IMIDAZOLE 1 CARBOXYLATE; 10 TERT BUTYL 14,16 DIMETHYL 2,2 DIMETHYL 4,12 DIOXO 3,13 DIOXA 5,11 DIAZAHEXADECANE 10,14,16 TRICARBOXYLATE; 2 [3 [5 (4 BROMO 2 FLUOROBENZAMIDO) 1 CARBOXYPENTYL]UREIDO]PENTANEDIOIC ACID; 2 [3 [5 (4 IODO 2 FLUOROBENZAMIDO) 1 CARBOXYPENTYL]UREIDO]PENTANEDIOIC ACID; 2 [[(5 AMINO 1 CARBOXYPENTYL)CARBAMOYL]OXY]PENTANEDIOIC ACID; 2 [[1 CARBOXY 5 (2 FLUORO 4 IODOBENZAMIDOPENTYL)CARBAMOYL]OXY]PENTANEDIOIC ACID; 2 [[[(5 AMINO 1 CARBOXYPENTYL)OXY]CARBONYL]AMINO]PENTANEDIOIC ACID TRIFLUOROACETIC ACID SALT; 2 [[[1 CARBOXY 5 (4 FLUOROBENZAMIDO)PENTYL]CARBAMOYL]OXY]PENTANEDIOIC ACID; 2 [[[5 (4 BROMO 2 FLUOROBENZAMIDO) 1 CARBOXYPENTYL]CARBAMOYL]OXY]PENTANEDIOIC ACID; 2 [[[[1 CARBOXY 5 (4 FLUOROBENZAMIDO)PENTYL]OXY]CARBONYL]AMINO]PENTANEDIOIC ACID; CARBAMIC ACID DERIVATIVE; DIMETHYL 2 [(1H IMIDAZOLE 1 CARBONYL)OXY]PENTANEDIOATE; GLUTARIC ACID; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TERT BUTYL 6 [(TERT BUTOXYCARBONYL)AMINO] 2 HYDROXYHEXANOATE; TRACER; TRI TERT BUTYL 2,2 DIMETHYL 4,12 DIOXO 3,11 DIOXA 5,13 DIAZAHEXADECANE 10,14,16 TRICARBOXYLATE; UNCLASSIFIED DRUG; FLUORINE; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; VALERIC ACID DERIVATIVE;

ANIMAL TISSUE; ARTICLE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER CELL LINE; RADIOCHEMISTRY; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; DIAGNOSTIC IMAGING; DRUG SCREENING; DRUG STABILITY; FEMALE; KIDNEY; METABOLISM; PROCEDURES; PROSTATE; SCID MOUSE; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CARBAMATES; CELL LINE, TUMOR; DRUG STABILITY; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; KIDNEY; MALE; MICE; MICE, SCID; MOLECULAR DOCKING SIMULATION; ORGAN SPECIFICITY; PENTANOIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955083286     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01268     Document Type: Article

References (66)

1. Mesters, J. R.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B. S.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer EMBO J. 2006, 25 (6) 1375-84 10.1038/sj.emboj.7600969
2. Barinka, C.; Sacha, P.; Sklenar, J.; Man, P.; Bezouska, K.; Slusher, B. S.; Konvalinka, J. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity Protein Sci. 2004, 13 (6) 1627-35 10.1110/ps.04622104
3. Pinto, J. T.; Suffoletto, B. P.; Berzin, T. M.; Qiao, C. H.; Lin, S.; Tong, W. P.; May, F.; Mukherjee, B.; Heston, W. D. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells Clin. Cancer Res. 1996, 2 (9) 1445-51
4. Ghosh, A.; Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell. Biochem. 2004, 91 (3) 528-39 10.1002/jcb.10661
5. Rajasekaran, A. K.; Anilkumar, G.; Christiansen, J. J. Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol.: Cell Physiol. 2005, 288 (5) C975-81 10.1152/ajpcell.00506.2004
6. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma Urology 2001, 57 (6) 1179-83 10.1016/S0090-4295(01)00983-9
7. Bander, N. H.; Milowsky, M. I.; Nanus, D. M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S. J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer J. Clin. Oncol. 2005, 23 (21) 4591-601 10.1200/JCO.2005.05.160
8. Perner, S.; Hofer, M. D.; Kim, R.; Shah, R. B.; Li, H.; Moller, P.; Hautmann, R. E.; Gschwend, J. E.; Kuefer, R.; Rubin, M. A. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression Hum. Pathol. 2007, 38 (5) 696-701 10.1016/j.humpath.2006.11.012
9. Byun, Y.; Mease, R. C.; Lupold, S.; Pomper, M. G. Recent Developments of Diagnostic and Therapeutic Agents Targeting Glutamate Carboxypeptidase II (GCPII). In Drug Design of Zinc-Enzyme Inhibitors: Functional Structureal and Disease Applications; Supuran, C. T.; Winum, J. Y., Eds.; John Wiley & Sons: Hoboken, NJ, 2009; pp 881-910, DOI: 10.1002/9780470508169.ch36.
10. Tsukamoto, T.; Wozniak, K. M.; Slusher, B. S. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors Drug Discovery Today 2007, 12 (17-18) 767-76 10.1016/j.drudis.2007.07.010
11. Zhou, J.; Neale, J. H.; Pomper, M. G.; Kozikowski, A. P. NAAG peptidase inhibitors and their potential for diagnosis and therapy Nat. Rev. Drug Discovery 2005, 4 (12) 1015-26 10.1038/nrd1903
12. Jackson, P. F.; Cole, D. C.; Slusher, B. S.; Stetz, S. L.; Ross, L. E.; Donzanti, B. A.; Trainor, D. A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase J. Med. Chem. 1996, 39 (2) 619-22 10.1021/jm950801q
13. Jackson, P. F.; Tays, K. L.; Maclin, K. M.; Ko, Y. S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X. C.; Wozniak, K.; Slusher, B. S. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors J. Med. Chem. 2001, 44 (24) 4170-5 10.1021/jm0001774
14. Maung, J.; Mallari, J. P.; Girtsman, T. A.; Wu, L. Y.; Rowley, J. A.; Santiago, N. M.; Brunelle, A. N.; Berkman, C. E. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates Bioorg. Med. Chem. 2004, 12 (18) 4969-79 10.1016/j.bmc.2004.06.031
15. Kozikowski, A. P.; Nan, F.; Conti, P.; Zhang, J.; Ramadan, E.; Bzdega, T.; Wroblewska, B.; Neale, J. H.; Pshenichkin, S.; Wroblewski, J. T. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) J. Med. Chem. 2001, 44 (3) 298-301 10.1021/jm000406m
16. Kozikowski, A. P.; Zhang, J.; Nan, F.; Petukhov, P. A.; Grajkowska, E.; Wroblewski, J. T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J. H. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents J. Med. Chem. 2004, 47 (7) 1729-38 10.1021/jm0306226
17. Majer, P.; Jackson, P. F.; Delahanty, G.; Grella, B. S.; Ko, Y. S.; Li, W.; Liu, Q.; Maclin, K. M.; Polakova, J.; Shaffer, K. A.; Stoermer, D.; Vitharana, D.; Wang, E. Y.; Zakrzewski, A.; Rojas, C.; Slusher, B. S.; Wozniak, K. M.; Burak, E.; Limsakun, T.; Tsukamoto, T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor J. Med. Chem. 2003, 46 (10) 1989-96 10.1021/jm020515w
18. Stoermer, D.; Vitharana, D.; Hin, N.; Delahanty, G.; Duvall, B.; Ferraris, D. V.; Grella, B. S.; Hoover, R.; Rojas, C.; Shanholtz, M. K.; Smith, K. P.; Stathis, M.; Wu, Y.; Wozniak, K. M.; Slusher, B. S.; Tsukamoto, T. Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds J. Med. Chem. 2012, 55 (12) 5922-32 10.1021/jm300488m
19. Stoermer, D.; Liu, Q.; Hall, M. R.; Flanary, J. M.; Thomas, A. G.; Rojas, C.; Slusher, B. S.; Tsukamoto, T. Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II Bioorg. Med. Chem. Lett. 2003, 13 (13) 2097-100 10.1016/S0960-894X(03)00407-4
20. Foss, C. A.; Mease, R. C.; Cho, S. Y.; Kim, H. J.; Pomper, M. G. GCPII imaging and cancer Curr. Med. Chem. 2012, 19 (9) 1346-59 10.2174/092986712799462612
21. Mease, R. C.; Foss, C. A.; Pomper, M. G. PET imaging in prostate cancer: focus on prostate-specific membrane antigen Curr. Top. Med. Chem. 2013, 13 (8) 951-62 10.2174/1568026611313080008
22. Vargas, H. A.; Grimm, J.; Donati, O. F.; Sala, E.; Hricak, H. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm European radiology 2015, 25, 1294-1302 10.1007/s00330-014-3539-5
23. Chen, Y.; Foss, C. A.; Byun, Y.; Nimmagadda, S.; Pullambhatla, M.; Fox, J. J.; Castanares, M.; Lupold, S. E.; Babich, J. W.; Mease, R. C.; Pomper, M. G. Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer J. Med. Chem. 2008, 51 (24) 7933-7943 10.1021/jm801055h
24. Barinka, C.; Byun, Y.; Dusich, C. L.; Banerjee, S. R.; Chen, Y.; Castanares, M.; Kozikowski, A. P.; Mease, R. C.; Pomper, M. G.; Lubkowski, J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization J. Med. Chem. 2008, 51 (24) 7737-43 10.1021/jm800765e
25. Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) J. Med. Chem. 2008, 51 (15) 4504-17 10.1021/jm800111u
26. Banerjee, S. R.; Foss, C. A.; Pullambhatla, M.; Wang, Y.; Srinivasan, S.; Hobbs, R.; Baidoo, K. E.; Brechbiel, M. W.; Nimmagadda, S.; Mease, R. C.; Sgouros, G.; Pomper, M. G. Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates J. Nucl. Med. 2015, 56, 628-34 10.2967/jnumed.114.149062
27. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J. J.; Horti, A.; Mease, R. C.; Pomper, M. G. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer J. Med. Chem. 2010, 53 (14) 5333-41 10.1021/jm100623e
28. 64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer J. Med. Chem. 2014, 57 (6) 2657-69 10.1021/jm401921j
29. Chen, Y.; Pullambhatla, M.; Byun, Y.; Foss, C. A.; Nimmagadda, S.; Senthamizhchelvan, S.; Sgouros, G.; Mease, R. C.; Pomper, M. G. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-urei do)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET Imaging Agent for Prostate Cancer Clin. Cancer Res. 2011, 17, 7645-53 10.1158/1078-0432.CCR-11-1357
30. Eder, M.; Schafer, M.; Bauder-Wust, U.; Hull, W. E.; Wangler, C.; Mier, W.; Haberkorn, U.; Eisenhut, M. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging Bioconjugate Chem. 2012, 23 (4) 688-97 10.1021/bc200279b
31. Foss, C. A.; Mease, R. C.; Fan, H.; Wang, Y.; Ravert, H. T.; Dannals, R. F.; Olszewski, R. T.; Heston, W. D.; Kozikowski, A. P.; Pomper, M. G. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer Clin. Cancer Res. 2005, 11 (11) 4022-8 10.1158/1078-0432.CCR-04-2690
32. Hillier, S. M.; Maresca, K. P.; Lu, G.; Merkin, R. D.; Marquis, J. C.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer J. Nucl. Med. 2013, 54 (8) 1369-76 10.2967/jnumed.112.116624
33. Kularatne, S. A.; Zhou, Z.; Yang, J.; Post, C. B.; Low, P. S. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents Mol. Pharmaceutics 2009, 6 (3) 790-800 10.1021/mp9000712
34. Lapi, S. E.; Wahnishe, H.; Pham, D.; Wu, L. Y.; Nedrow-Byers, J. R.; Liu, T.; Vejdani, K.; VanBrocklin, H. F.; Berkman, C. E.; Jones, E. F. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer J. Nucl. Med. 2009, 50 (12) 2042-8 10.2967/jnumed.109.066589
35. Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.; Zimmerman, C. N.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C.; Babich, J. W. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer J. Med. Chem. 2009, 52 (2) 347-57 10.1021/jm800994j
36. Mease, R. C.; Dusich, C. L.; Foss, C. A.; Ravert, H. T.; Dannals, R. F.; Seidel, J.; Prideaux, A.; Fox, J. J.; Sgouros, G.; Kozikowski, A. P.; Pomper, M. G. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer Clin. Cancer Res. 2008, 14 (10) 3036-43 10.1158/1078-0432.CCR-07-1517
37. Ray Banerjee, S.; Pullambhatla, M.; Foss, C. A.; Falk, A.; Byun, Y.; Nimmagadda, S.; Mease, R. C.; Pomper, M. G. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA) J. Med. Chem. 2013, 56 (15) 6108-21 10.1021/jm400823w
38. Weineisen, M.; Simecek, J.; Schottelius, M.; Schwaiger, M.; Wester, H.-J., Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014, 4, DOI: 10.1186/s13550-014-0063-1
39. Afshar-Oromieh, A.; Avtzi, E.; Giesel, F. L.; Holland-Letz, T.; Linhart, H. G.; Eder, M.; Eisenhut, M.; Boxler, S.; Hadaschik, B. A.; Kratochwil, C.; Weichert, W.; Kopka, K.; Debus, J.; Haberkorn, U. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Eur. J. Nucl. Med. Mol. Imaging 2015, 42 (2) 197-209 10.1007/s00259-014-2949-6
40. Afshar-Oromieh, A.; Haberkorn, U.; Eder, M.; Eisenhut, M.; Zechmann, C. M. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH Eur. J. Nucl. Med. Mol. Imaging 2012, 39 (6) 1085-6 10.1007/s00259-012-2069-0
41. Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H. G.; Hadaschik, B. A.; Holland-Letz, T.; Giesel, F. L.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, C. M. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur. J. Nucl. Med. Mol. Imaging 2013, 40 (4) 486-95 10.1007/s00259-012-2298-2
42. Afshar-Oromieh, A.; Zechmann, C. M.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H. G.; Holland-Letz, T.; Hadaschik, B. A.; Giesel, F. L.; Debus, J.; Haberkorn, U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer Eur. J. Nucl. Med. Mol. Imaging 2014, 41 (1) 11-20 10.1007/s00259-013-2525-5
43. Barrett, J. A.; Coleman, R. E.; Goldsmith, S. J.; Vallabhajosula, S.; Petry, N. A.; Cho, S.; Armor, T.; Stubbs, J. B.; Maresca, K. P.; Stabin, M. G.; Joyal, J. L.; Eckelman, W. C.; Babich, J. W. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer J. Nucl. Med. 2013, 54 (3) 380-7 10.2967/jnumed.112.111203
44. Cho, S. Y.; Gage, K. L.; Mease, R. C.; Senthamizhchelvan, S.; Holt, D. P.; Jeffrey-Kwanisai, A.; Endres, C. J.; Dannals, R. F.; Sgouros, G.; Lodge, M.; Eisenberger, M. A.; Rodriguez, R.; Carducci, M. A.; Rojas, C.; Slusher, B. S.; Kozikowski, A. P.; Pomper, M. G. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer J. Nucl. Med. 2012, 53 (12) 1883-91 10.2967/jnumed.112.104661
45. Rowe, S.; Gage, K. L.; Macura, K.; Guner, G.; Faraj, S. F.; Munari, E.; Rodriquez, R.; Han, M.; Blackford, A.; Netto, G.; Lodge, M.; Mease, R. C.; Pomper, M. G.; Cho, S. Y. et al. 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer J. Nucl. Med. 2015, 56, 1003 10.2967/jnumed.115.154336
46. 18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Mol Imaging Biol. 2015, 17, 565 10.1007/s11307-015-0850-8
47. Vallabhajosula, S.; Nikolopoulou, A.; Babich, J. W.; Osborne, J. R.; Tagawa, S. T.; Lipai, I.; Solnes, L.; Maresca, K. P.; Armor, T.; Joyal, J. L.; Crummet, R.; Stubbs, J. B.; Goldsmith, S. J. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer J. Nucl. Med. 2014, 55 (11) 1791-8 10.2967/jnumed.114.140426
48. Wang, E. K.; Kolb, H. C.; Szardenings, A. K.; Liu, C.; Walsh, J. C.; Chen, G.; Sinha, A.; Kasi, D.; Yu, C.; Gangadharmath, U. B.; Zhang, W.; Zhao, T.; Mocharla, V. P. PSMA Imaging Agents. 2013.
49. Chen, Y.; Pullambhatla, M.; Banerjee, S. R.; Byun, Y.; Stathis, M.; Rojas, C.; Slusher, B. S.; Mease, R. C.; Pomper, M. G. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen Bioconjugate Chem. 2012, 23 (12) 2377-85 10.1021/bc3003919
50. Kabalka, G. W.; Mereddy, A. R. A facile no-carrier-added radioiodination procedure suitable for radiolabeling kits Nucl. Med. Biol. 2004, 31 (7) 935-8 10.1016/j.nucmedbio.2004.05.005
51. Zalutsky, M. R.; Narula, A. S. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine Int. J. Rad Appl. Instrum Part A 1987, 38, 1051-1055 10.1016/0883-2889(87)90069-4
52. 18F]fluorophenylalanine J. Fluorine Chem. 1996, 80, 117-124 10.1016/S0022-1139(96)03488-4
53. 18F]SFB J. Labelled Compd. Radiopharm. 2009, 52, 327-330 10.1002/jlcr.1601
54. Zhong, C.; Zhao, X.; Sarva, J.; Kozikowski, A.; Neale, J. H.; Lyeth, B. G. NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats J. Neurotrauma 2005, 22 (2) 266-76 10.1089/neu.2005.22.266
55. Wang, H.; Byun, Y.; Barinka, C.; Pullambhatla, M.; Bhang, H. E.; Fox, J. J.; Lubkowski, J.; Mease, R. C.; Pomper, M. G. Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies Bioorg. Med. Chem. Lett. 2010, 20 (1) 392-7 10.1016/j.bmcl.2009.10.061
56. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues Clin. Cancer Res. 1997, 3 (1) 81-5
57. Slusher, B. S.; Tsai, G.; Yoo, G.; Coyle, J. T. Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase) J. Comp. Neurol. 1992, 315 (2) 217-29 10.1002/cne.903150208
58. Reske, S. N.; Winter, G.; Baur, B.; Machulla, H. J.; Kull, T. Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur. J. Nucl. Med. Mol. Imaging 2013, 40 (6) 969-70 10.1007/s00259-013-2385-z
59. Zechmann, C. M.; Afshar-Oromieh, A.; Armor, T.; Stubbs, J. B.; Mier, W.; Hadaschik, B.; Joyal, J.; Kopka, K.; Debus, J.; Babich, J. W.; Haberkorn, U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy Eur. J. Nucl. Med. Mol. Imaging 2014, 41 (7) 1280-92 10.1007/s00259-014-2713-y
60. Afshar-Oromieh, A.; Haberkorn, U.; Hadaschik, B.; Habl, G.; Eder, M.; Eisenhut, M.; Schlemmer, H. P.; Roethke, M. C. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer Eur. J. Nucl. Med. Mol. Imaging 2013, 40 (10) 1629-30 10.1007/s00259-013-2489-5
61. 177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 987 10.1007/s00259-014-2978-1
62. Makarasen, A.; Nishikawa, T.; Isobe, M. Synthesis of four lysine-linked cereulide analogues showing ionophoric activity towards potassium cations as lead compounds for emetic toxin detection by immunoassays Synthesis 2009, 2009, 2184-2004 10.1055/s-0029-1216837
63. Litosh, V. A.; Hersh, M. N.; Stupi, B. P.; Wu, W.; Metzker, M. L. Nucleotides and nucleosides and methods for their use in DNA sequencing. Patent WO2009152353 A2, 2009
64. Winkler, J. W.; Uddin, J.; Serhan, C. N.; Petasis, N. A. Stereocontrolled total synthesis of the potent anti-inflammatory and pro-resolving lipid mediator resolvin D3 and its aspirin-triggered 17R-epimer Org. Lett. 2013, 15 (7) 1424-7 10.1021/ol400484u
65. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constate (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108 10.1016/0006-2952(73)90196-2
66. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res. 1999, 59 (13) 3192-8